Hologic's Preliminary Revenue Results Highlight Growth
Hologic, Inc. (Nasdaq: HOLX) has announced its preliminary revenue results for the first fiscal quarter that ended recently. Initial figures indicate that the company anticipates reporting total revenues of approximately $1,021.8 million. This marks an increase of 0.9% from the same period last year, which translates to approximately 1.0% in constant currency.
Insights from the Chief Financial Officer
Karleen Oberton, the company's Chief Financial Officer, shared insights regarding the results. She noted that despite facing challenges due to the strengthening U.S. dollar, which negatively impacted revenue by around $9 million, the company's earnings per share are expected to be at the high end of the guidance range.
Revenues Breakdown by Division
The company provided a breakdown of expected revenues by division, shedding light on where growth is occurring. The Diagnostics division is expected to lead with revenues of approximately $470.6 million, rising from $447.8 million in the prior year. This reflects a robust growth rate of 5.1%. Additionally, organic revenues excluding COVID-19 have also shown promising figures.
Performance in Breast Health and GYN Surgical Areas
In the Breast Health division, revenue is projected to reach $369.1 million, a slight decline from $377.7 million the previous year, which indicates a decrease of 2.3%. On the other hand, GYN Surgical revenues are on the rise, expected to generate $166.3 million, demonstrating a 2.5% increase compared to the same quarter last year.
Anticipated Financial Guidance
As Hologic has not finalized its financial close processes for this quarter, GAAP financial results are still pending. However, expectations for non-GAAP diluted earnings per share remain optimistic, aligning closely with the high-end guidance ranges announced previously.
Future Financial Results Announcements
Hologic plans to release its comprehensive financial results for the first quarter in early February. This will include updated guidance for the upcoming second quarter and the full fiscal year of 2025.
Participation in Healthcare Conference
The company is also preparing for its participation in the upcoming J.P. Morgan Healthcare Conference. This platform will allow Hologic to present its latest findings and answer investor inquiries regarding its strategic direction and financial performance.
Understanding Non-GAAP Financial Measures
Hologic has adopted various non-GAAP financial measures to provide clarity and insight into its operations. These include measures like constant currency revenues and organic revenue results excluding specific items, allowing for a comprehensive view of the company's financial health.
About Hologic, Inc.
Hologic, Inc. is dedicated to improving women's health through innovative medical technology. The company focuses on early detection and treatment, striving to enhance the well-being of women worldwide. For more information about Hologic and its initiatives, interested individuals can visit their corporate website.
Frequently Asked Questions
What were Hologic's preliminary revenue results?
Hologic reported preliminary revenue results of approximately $1,021.8 million for the first quarter of fiscal 2025, a growth of 0.9% year-over-year.
How did the currency exchange impact Hologic's results?
The strengthening of the U.S. dollar reduced revenue by about $9 million compared to previous guidance.
When will Hologic release its full financial results?
Hologic is expected to announce its detailed financial results for the first quarter on February 5, 2025.
What divisions contributed to Hologic's revenue growth?
The Diagnostics and GYN Surgical divisions showed notable revenue increases, while Breast Health experienced a slight decline.
What is Hologic's focus as a company?
Hologic, Inc. is focused on innovative medical technologies to improve women's health through early detection and treatment solutions.
